Cargando…

T315I(+) tyrosine-kinase independent CML cells resistance

Detalles Bibliográficos
Autores principales:	Nicolini, Franck Emmanuel, Grockowiak, Elodie, Maguer-Satta, Véronique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546427/ https://www.ncbi.nlm.nih.gov/pubmed/28642447 http://dx.doi.org/10.18632/oncotarget.18573

Ejemplares similares

Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
por: Trinh, Anne, et al.
Publicado: (2021)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission
por: Jeanpierre, Sandrine, et al.
Publicado: (2020)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
por: Kuzmina, Elena, et al.
Publicado: (2023)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
por: Xu, Peipei, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy
por: Gómez-Castañeda, Eduardo, et al.
Publicado: (2022)

T Cell Development and T Cell Responses in Mice with Mutations Affecting Tyrosines 292 or 315 of the Zap-70 Protein Tyrosine Kinase
por: Magnan, Antoine, et al.
Publicado: (2001)

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
por: Eadie, Laura N., et al.
Publicado: (2016)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL
por: Ru, Yi, et al.
Publicado: (2016)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

An interesting case of chronic myeloid leukemia (CML) with T315I mutation raising suspicion of de novo AML, a diagnostic conundrum
por: Iqbal, Phool, et al.
Publicado: (2023)

LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent
por: Zweytick, Dagmar
Publicado: (2019)

Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study
por: Banavath, Hemanth Naick, et al.
Publicado: (2014)

Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
por: Zhou, Lu, et al.
Publicado: (2019)

Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant
por: Jin, Bei, et al.
Publicado: (2018)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells
por: Kaehler, Meike, et al.
Publicado: (2022)

A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
por: Nicolini, Franck-Emmanuel, et al.
Publicado: (2023)

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML
por: Ono, Takaaki, et al.
Publicado: (2022)

T315I-mutated myeloid sarcoma
por: Zhang, Yumeng, et al.
Publicado: (2019)

BMP2, a key to uncover luminal breast cancer origin linked to pollutant effects on epithelial stem cells niche
por: Chapellier, Marion, et al.
Publicado: (2015)

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
por: Cerveira, Nuno, et al.
Publicado: (2018)

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells
por: Malyukova, Alena, et al.
Publicado: (2021)

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
por: Sanchez, María Belén, et al.
Publicado: (2023)

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics
por: Carpiuc, Kimbach Tran, et al.
Publicado: (2010)

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor
por: Vaidya, Shantashri, et al.
Publicado: (2015)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

Exosomes from Bone Marrow Microenvironment-Derived Mesenchymal Stem Cells Affect CML Cells Growth and Promote Drug Resistance to Tyrosine Kinase Inhibitors
por: Zhang, Xiaoyan, et al.
Publicado: (2020)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Chk-mate on resistance to kinase inhibitors
por: Shapiro, Paul
Publicado: (2018)

Early Steps of Mammary Stem Cell Transformation by Exogenous Signals; Effects of Bisphenol Endocrine Disrupting Chemicals and Bone Morphogenetic Proteins
por: Jung, Nora, et al.
Publicado: (2019)

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation
por: Du, Zhuanyun, et al.
Publicado: (2022)

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
por: Mauro, Michael J., et al.
Publicado: (2023)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

Requirement for Tyrosine Residues 315 and 319 within ζ Chain–Associated Protein 70 for T Cell Development
por: Gong, Qian, et al.
Publicado: (2001)

The First Reported Case of Allogenic Hematopoietic Stem Cell Transplantation for CML Blast Phase (Monocytic Lineage) in the Tyrosine Kinase Inhibitor Era
por: Yamada, Shinya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ndgs3p7ogoq350cfnindkccc4r